Wet Age-Related Macular Degeneration
Eylea HD meets primary endpoint of improved vision in phase 3 retinal vein occlusion trial
Eylea HD improved vision with extended dosing intervals in patients with macular edema following retinal vein occlusion in the phase 3 QUASAR trial, according to a press release from Regeneron.
European committee issues positive opinion for Eylea biosimilar
The Committee for Medicinal Products for Human Use of the European Medicines Agency granted a positive opinion for Eydenzelt, a biosimilar to Eylea, according to a press release from Celltrion.
Vabysmo prefilled syringe receives European approval
The European Medicines Agency approved the Vabysmo 6 mg prefilled syringe for three retinal conditions, according to a press release from Roche.
Geographic Atrophy Secondary to AMD: Optimizing Patient Selection for Novel Therapeutics
This activity is supported by educational grants from Astellas and Topcon Healthcare, Inc.
More than 300 patients assigned to treatment in phase 3 trial of Axpaxli for wet AMD
Ocular Therapeutix announced that more than 300 patients have been randomly assigned in the SOL-1 phase 3 trial for Axpaxli, an investigational axitinib intravitreal implant for wet age-related macular degeneration.
Post hoc analysis of PULSAR data shows sustained fluid control with Eylea HD
BARCELONA, Spain — A post hoc analysis of PULSAR trial data showed sustained fluid control at 2 years with fewer injections and longer dosing intervals in patients treated with aflibercept 8 mg for wet age-related macular degeneration.
Patient dosing underway in phase 3 LUCIA trial of Duravyu for wet AMD
The first patient underwent dosing in the phase 3 LUCIA clinical trial of Duravyu for wet age-related macular degeneration, according to a press release from EyePoint Pharmaceuticals.
VIDEO: Greater improvements seen with dual pathway therapy in retinal diseases
NEW YORK — In this Healio Video Perspective from OSN New York Retina, Rishi P. Singh, MD, FASRS, discusses biomarkers for angiopoietin-2 and VEGF inhibition in wet age-related macular degeneration and diabetic macular edema.
Adverum reports positive 52-week, 4-year data for wet AMD gene therapy
Adverum Biotechnologies reported positive 52-week data from the phase 2 LUNA trial as well as long-term follow-up results from the OPTIC trial of Ixo-vec in patients with wet age-related macular degeneration.
VIDEO: EYP-1901 shows positive vision, treatment burden outcomes at 1 year
CHICAGO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Carl D. Regillo, MD, FACS, of Wills Eye Hospital, shares study results from the phase 2 DAVIO 2 trial.